The drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. But the advisory panel said there was not enough evidence of its effectiveness in slowing cognitive decline.
The Arizona Alzheimer’s Consortium honors philanthropist Michael Zuendel for extraordinary contributions to the scientific, clinical, and social fight against Alzheimer’s disease
PHOENIX, Ariz. – On Saturday, May 17 the Arizona Alzheimer’s Consortium will hold its always-anticipated public conference. This free event gathers more than 200 patients, caregivers, family members, and interested persons together with researchers, caregiving...